New drug cocktail aims to tackle tough skin cancer

NCT ID NCT07535710

Not yet recruiting Disease control Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of four chemotherapy drugs (aclarubicin, cyclophosphamide, vincristine, and prednisone) in people with cutaneous T-cell lymphoma that has come back or not responded to prior treatment. The trial has two phases: first, finding the safest dose of aclarubicin, and second, measuring how many patients see their tumors shrink. About 37 adults aged 60 and older will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aclarubicin (a type of chemotherapy) combined with cyclophosphamide, vincristine, and prednisone
What this could lead to: If successful, this could provide a new chemotherapy option for patients with cutaneous T-cell lymphoma that has stopped responding to other treatments.
What could go wrong: This is an early-phase trial with only 37 participants, so results may not apply to everyone. The drug combination may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA (CTCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary cutaneous T-cell non-Hodgkin lymphoma Recurrence Sezary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS T CELL LYMPHOMA (CTCL) CUTANEOUS T-CELL LYMPHOMA REFRACTORY CUTANEOUS T-CELL LYMPHOMA, RELAPSED SEZARY SYNDROME

Contacts and locations

Locations

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

Shanghai, China
Ruijin Hospital Wuxi Branch

Wuxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.